Acura Provides Update on Opioid Product; Boston Scientific Announces Favorable Ruling Print E-mail
By Staff and Wire Reports   
Monday, 23 January 2012 20:58
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 23, 2012.

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company, announced it has been informed by Pfizer, Inc. (NYSE: PFE) that OXECTA® (oxycodone HCl, USP) Tablets CII is now commercially available. OXECTA, which utilizes Acura's AVERSION® Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg dosage strengths.

"The commercial availability of OXECTA is an important milestone and we are pleased Pfizer continues to advance the commercialization plan for OXECTA," said Bob Jones, chief executive officer of Acura Pharmaceuticals.

Acura has exclusively licensed the AVERSION Technology to Pfizer in the United States, Canada and Mexico for use in four opioid-based pain products. Acura receives tiered royalties ranging from 5% to 25% on net sales (gross sales less discounts, if any) of OXECTA commencing on the first anniversary of the first commercial sale of OXECTA. Pfizer has an option to license the use of the AVERSION technology with additional opioids.

----

Boston Scientific Corporation (NYSE:BSX) announces the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson to be invalid and entered judgment in favor of Boston Scientific.

As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents").  The patents relate to the use of a drug on a drug-eluting stent.

"We are pleased with the Court's finding that both of these Johnson & Johnson patents are invalid," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.  "Boston Scientific will continue to vigorously defend against any claims of infringement."



Also Monday:



Advanced Cell Technology, Inc. (OTCBB: ACTC)
, a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancetas anearly online publication demonstrate the safety of ACT’s human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD).

Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established an Extracorporeal Therapy Scientific Advisory Board to guide the advancement of the Aethlon Hemopurifier® and other therapies developed from the Aethlon ADAPT™ system.

Array BioPharma Inc. (NASDAQ:ARRY) will report financial results for the second quarter of fiscal 2012 on Monday, January 30, 2012, and will hold a conference call on Tuesday, January 31, 2012 at 9:00 a.m. eastern time to discuss these results.

BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells,  tissues, and organs, today announced that three additional key opinion leaders in the biobanking, drug discovery, and regenerative medicine markets have joined the Company's Scientific Advisory Board (SAB).

BioRestorative Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it will be presenting at the Seventh International Conference on Cell Therapy for Cardiovascular Disease.

Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM)
("Biostar" or "the Company"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, today announced that on January 8th it was one of nine PRC pharmaceutical companies selected to cooperate with The Fourth Military Medical University ("FMMU") (website: http://en.fmmu.edu.cn) in the fields of research and product development.

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P. ("IDG"), Emerging Technology Partners, LLC ("ETP"), and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.

Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, is pleased to announce that its advertising contract with Clear Channel Los Angeles (CCLA) has been extended until January 31, 2013.

Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY)
a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

IGEN Networks Corporation (IGEN: OTCBB) and privately held Machlink Corporation are pleased to announce definitive agreements for both distribution and the purchase of equity between the companies. Consistent with their respective business plans and for the mutual benefits of both companies, IGEN and Machlink will work together to market a wireless extension of HFC broadband infrastructure along with M2M video analytic solutions for enterprise and commercial markets.

Medtronic, Inc. (NYSE:MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company’s Advanced Energy business.

NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that its Chief Medical Officer, the lead investigator for its PreSERVE Phase 2 clinical trial for AMR-001 for preservation of heart function in post acute myocardial infarction patients, and the President of its subsidiary, Progenitor Cell Therapy, LLC, have been invited to present at the Seventh International Conference on Cell Therapy for Cardiovascular Disease held from January 25-27, 2012 in New York City.

Solazyme, Inc. (NASDAQ:SZYM)
, a renewable oil and bioproducts company, announced today that Maersk Line, one of the biggest shipping companies in the world, has completed the testing of Solazyme’s 100% algal derived renewable diesel as part of an integrated testing and certification program with the U.S. Navy.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter